Amyloid-Journal of Protein Folding Disorders

Papers
(The H4-Index of Amyloid-Journal of Protein Folding Disorders is 14. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)
ArticleCitations
Therapeutic effect of TTR siRNA on hereditary transthyretin amyloidosis (ATTRv) nephropathy215
Tissue biopsy for the diagnosis of amyloidosis: experience from some centres190
Re-evaluation of Mayo 2004 and revised Mayo 2012 staging in patients with AL amyloidosis in the era of new therapies92
Changes in the amyloid editorial board members and in editor positions76
A second case of liraglutide-type localised amyloidosis59
Phenotype and clinical outcomes of Glu89Lys hereditary transthyretin amyloidosis: a new endemic variant in Spain40
The way to a man’s heart: prostate samples for the early detection of transthyretin cardiomyopathy34
Iatrogenic cerebral amyloid angiopathy rather than sporadic CAA in younger adults with lobar intracerebral haemorrhage28
Effects of eplontersen on symptoms of autonomic neuropathy in hereditary transthyretin-mediated amyloidosis: secondary analysis from the NEURO-TTRansform trial26
Oxidative conversion of transthyretin in formalin-fixed clinical amyloid samples results in the formation of the His90Asp and His90Asn variants20
Whole tissue proteomic analyses of cardiac ATTR and AL unveil mechanisms of tissue damage19
In memoriam: Lawreen Connors, Ph.D.19
Post-translational modification of amyloid a protein in patients with AA amyloidosis17
Diagnostic and prognostic contribution of DPD scintigraphy in transthyretin V30M cardiac amyloidosis17
Brain MRI in patients with V30M hereditary transthyretin amyloidosis14
A multicentric study of the disease risks and first manifestations in hereditary transthyretin amyloidosis (ATTRv): insights for an earlier diagnosis14
Refining prognostication in systemic AL amyloidosis: limited value of dFLC14
Utilization and tolerance of beta-blockers among patients with AL amyloidosis14
0.88433384895325